SAM advised Emcure Pharmaceuticals Limited, a leading Indian pharmaceutical company, for its recently concluded USD 234 million IPO
Khaitan & Co served as legal advisors to the Book Running Lead Managers—KOTAK MAHINDRA CAPITAL COMPANY LIMITED, Axis Capital Ltd., Jefferies India Private Limited, and J.P. Morgan India—in Emcure Pharmaceuticals Limited’s IPO
The IPO featured a fresh issue of equity shares amounting to INR 8,000 million and an offer for sale totaling INR 11,520.27 million.
Impressively, the IPO was oversubscribed by 68.50 times overall, with the QIB segment seeing an oversubscription of 190.88 times.
SAM’s team comprised Nikhil Naredi (Partner) with assistance from Priya Awasthi (Partner), Rakshita Poddar (Associate) and Manish Soni(Associate).
The KhaitanCo deal team comprised Chirayu Chandani, Aditya George Cheriyan, Tishita Mukherjee, Hrithik Khurana, Kaushlendra Singh Palawat, and Shreya Iyer.
Emcure Pharmaceuticals Limited, based in Pune, India, is a multinational pharmaceutical company with a diverse product portfolio. Their offerings include tablets, softgel and hard-gel capsules, and injectables. The company specializes in drugs for gynecology, cardiovascular health, oncology, blood therapeutics, HIV antivirals, other anti-infectives, as well as vitamins and minerals.
Share your news, articles, deals, columns, or press releases with us! Click the link to submit and join our platform today.
